Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC).
Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, Tomasello G, Vaglio A, Labianca R, Rondini E, Sabbatini R, Nastasi G, Artioli F, Prati A, Potenzoni M, Pezzuolo D, Oliva E, Alberici F, Buzio C; POLAR-01 Trial Investigators. Passalacqua R, et al. J Immunother. 2014 Nov-Dec;37(9):440-7. doi: 10.1097/CJI.0000000000000055. J Immunother. 2014. PMID: 25304727 Clinical Trial.
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
Di Costanzo F, Gasperoni S, Malacarne P, Belsanti V, Luppi G, Marzola M, Corgna E, Sdrobolini A, Passalacqua R, Figoli F, Algeri R, Zironi S, Angiona S, Boni C. Di Costanzo F, et al. Among authors: passalacqua r. Am J Clin Oncol. 1998 Aug;21(4):369-75. doi: 10.1097/00000421-199808000-00011. Am J Clin Oncol. 1998. PMID: 9708636 Clinical Trial.
Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G, Bella M, Lottici R, Leonardi F, Ceci G, Passalacqua R, Di Blasio B, Bordi C, Biscottini B, Melpignano M, De Biasi D, Finardi C, Bacchi M. Cocconi G, et al. Among authors: passalacqua r. Am J Clin Oncol. 1999 Dec;22(6):559-67. doi: 10.1097/00000421-199912000-00005. Am J Clin Oncol. 1999. PMID: 10597739 Clinical Trial.
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study.
Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A, Passalacqua R, Bian AR, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V, Cocconi G, Tonato M. Colozza M, et al. Among authors: passalacqua r. Eur J Cancer. 2002 Nov;38(17):2279-88. doi: 10.1016/s0959-8049(02)00452-5. Eur J Cancer. 2002. PMID: 12441265 Clinical Trial.
174 results